학술논문

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
Document Type
article
Source
Bone Reports, Vol 16, Iss , Pp 101582- (2022)
Subject
Bone turnover markers
Denosumab
Osteoporosis
Vertebral fractures
Rebound phenomenon
Diseases of the musculoskeletal system
RC925-935
Language
English
ISSN
2352-1872
Abstract
Denosumab is a commonly used antiresorptive treatment in patients with osteoporosis or solid tumours with bone metastases. Upon denosumab discontinuation, a rebound phenomenon can occur that results in an increased (vertebral) fracture risk. This phenomenon is well-known in the setting of osteoporosis but rarely reported in cancer patients with bone metastases discontinuing denosumab. We present the case of a 43-year old women with lung cancer and bone metastases who suffered multiple vertebral fractures after discontinuation of denosumab.